Search results for "ASSOCIATION"

showing 10 items of 1747 documents

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease

2017

International audience; We identified rare coding variants associated with Alzheimer's disease in a three-stage case-control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a whole-exome microarray. In stage 2, we tested associated variants (P < 1 × 10-4) in 35,962 independent samples using de novo genotyping and imputed genotypes. In stage 3, we used an additional 14,997 samples to test the most significant stage 2 associations (P < 5 × 10-8) using imputed genotypes. We observed three new genome-wide significant nonsynonymous variants associated with Alzheimer's disease: a protective variant in PLCG2 (rs72824905: p.Pro522Arg, P = 5.38 × 10-10, odds ratio (OR) = 0.68…

0301 basic medicineLinkage disequilibrium[SDV]Life Sciences [q-bio]MedizinSequence HomologyGenome-wide association studygenetics [Alzheimer Disease]metabolism [Microglia]Linkage Disequilibrium0302 clinical medicinegenetics [Protein Interaction Maps]genetics [Membrane Glycoproteins]Gene FrequencyImmunologicgenetics [Adaptor Proteins Signal Transducing]Receptorsgenetics [Exome]Odds RatioInnategenetics [Receptors Immunologic]ExomeProtein Interaction Mapsgenetics [Genetic Predisposition to Disease]Receptors ImmunologicABI3 protein humanGeneticsAdaptor Proteins Signal Transducing; Alzheimer Disease; Amino Acid Sequence; Case-Control Studies; Exome; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Immunity Innate; Linkage Disequilibrium; Membrane Glycoproteins; Microglia; Odds Ratio; Phospholipase C gamma; Protein Interaction Maps; Receptors Immunologic; Sequence Homology Amino Acid; Polymorphism Single Nucleotide; GeneticsMembrane GlycoproteinsAdaptor ProteinsSingle NucleotideAdaptor Proteins Signal Transducing; Alzheimer Disease; Amino Acid Sequence; Case-Control Studies; Exome; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Immunity Innate; Linkage Disequilibrium; Membrane Glycoproteins; Microglia; Odds Ratio; Phospholipase C gamma; Protein Interaction Maps; Receptors Immunologic; Sequence Homology Amino Acid; Polymorphism Single Nucleotide3. Good health[SDV] Life Sciences [q-bio]Amino AcidSettore MED/26 - NEUROLOGIAgenetics [Phospholipase C gamma][SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]MicrogliaAlzheimer's diseaseCommon disease-common variantGenotypeBiologyPolymorphism Single NucleotideArticle03 medical and health sciencesAlzheimer Diseaseddc:570medicineJournal ArticleGeneticsHumansGenetic Predisposition to Disease[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Amino Acid SequencePolymorphismAllele frequencyAdaptor Proteins Signal TransducingTREM2 protein humanSequence Homology Amino AcidTREM2Phospholipase C gammaGene Expression ProfilingCase-control studySignal TransducingImmunitymedicine.diseaseR1Immunity InnateMinor allele frequencygenetics [Immunity Innate]030104 developmental biologyCase-Control StudiesHuman medicine030217 neurology & neurosurgery
researchProduct

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals

2017

AbstractNonalcoholic fatty liver disease (NAFLD) represents an emerging cause of hepatocellular carcinoma (HCC), especially in non-cirrhotic individuals. The rs641738 C &gt; T MBOAT7/TMC4 variant predisposes to progressive NAFLD, but the impact on hepatic carcinogenesis is unknown. In Italian NAFLD patients, the rs641738 T allele was associated with NAFLD-HCC (OR 1.65, 1.08–2.55; n = 765), particularly in those without advanced fibrosis (p &lt; 0.001). The risk T allele was linked to 3’-UTR variation in MBOAT7 and to reduced MBOAT7 expression in patients without severe fibrosis. The number of PNPLA3, TM6SF2, and MBOAT7 risk variants was associated with NAFLD-HCC independently of clinical fa…

0301 basic medicineLiver CirrhosisMaleAlcoholic liver diseasePathologyCirrhosisliver diseasesGastroenterology0302 clinical medicineSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasefatty liver-disease; cirrhosis; liver cancer; hepatitis C; hepatocellular carcinoma; liver diseases; fibrosis; carcinogenesis; fatty liver; allelesHCCProspective cohort studySettore MED/12 - GastroenterologiaMultidisciplinaryLiver NeoplasmsQRhepatocellular carcinomaSingle NucleotideMiddle Aged3. Good healthItalyfatty liver-diseaseHepatocellular carcinomaCohortMedicine030211 gastroenterology & hepatologyFemalecarcinogenesisAcyltransferases; Adult; Aged; Carcinoma Hepatocellular; Female; Gene Expression Regulation; Genotype; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Non-alcoholic Fatty Liver Disease; Polymorphism Single Nucleotide; Risk Factors; Alleles; Genetic Association Studies; Genetic Predisposition to Disease; Genetic VariationAdultmedicine.medical_specialtyCarcinoma HepatocellularGenotypeSciencePolymorphism Single NucleotideArticleliver cancer03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseAllelePolymorphismAllelesGenetic Association Studiesfatty liverAgedSettore MED/06 - ONCOLOGIA MEDICAbusiness.industrycirrhosisfibrosisCarcinomaGenetic VariationMembrane ProteinsHepatocellularmedicine.diseasedigestive system diseases030104 developmental biologyGene Expression Regulationhepatitis CbusinessAcyltransferasesTM6SF2Scientific Reports
researchProduct

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND &amp; AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

Molecular, clinical and neuropsychological study in 31 patients with Kabuki syndrome and KMT2D mutations

2017

IF 3.326; International audience; Kabuki syndrome (KS-OMIM 147920) is a rare developmental disease characterized by the association of multiple congenital anomalies and intellectual disability. This study aimed to investigate intellectual performance in children with KS and link the performance to several clinical features and molecular data. We recruited 31 children with KMT2D mutations who were 6 to 16 years old. They all completed the Weschler Intelligence Scale for Children, fourth edition. We calculated all indexes: the Full Scale Intellectual Quotient (FSIQ), Verbal Comprehension Index (VCI), Perceptive Reasoning Index (PRI), Processing Speed Index (PSI), and Working Memory Index (WMI…

0301 basic medicineMaleAdolescentVisual impairmentDNA Mutational AnalysisIntelligenceneuropsychologyDisease[SDV.GEN] Life Sciences [q-bio]/GeneticsNeuropsychological Testsgenotype-phenotype correlation03 medical and health sciencesIntensive careIntellectual disabilityGene OrderGeneticsmedicineHumansAbnormalities MultipleChildKMT2D mutationGenetics (clinical)AllelesGenetic Association Studies[SDV.GEN]Life Sciences [q-bio]/GeneticsKabuki syndromebusiness.industryWorking memoryNeuropsychologyWechsler Adult Intelligence Scalemedicine.diseaseHematologic Diseases3. Good healthNeoplasm ProteinsDNA-Binding Proteins030104 developmental biologyPhenotypeVestibular DiseasesGenetic LociFaceMutationFemalemedicine.symptombusinessKabuki syndromeClinical psychology
researchProduct

Telomere length and physical performance among older people-The Helsinki Birth Cohort Study.

2019

Telomere length has been suggested a biomarker of aging and is associated with several chronic diseases. However, the association between telomere length and physical performance is not well known. Using both cross-sectional and longitudinal data, we studied 582 women and 453 men from the Helsinki Birth Cohort Study at two time-points; a baseline examination in 2001-2004 at a mean age of 61 years and a follow-up examination approximately 10 years later in 2011-2013. Telomere length was measured both at baseline and at follow-up using real-time quantitative polymerase chain reaction. Physical performance was evaluated only at follow-up using the Senior Fitness Test (SFT), which assesses stre…

0301 basic medicineMaleAgingBLOODFITNESSEpidemiologybiomarkkeritCAPABILITY0302 clinical medicineMARKERSEpidemiologyMedicine2. Zero hungerSex CharacteristicsASSOCIATIONMiddle AgedTelomere3142 Public health care science environmental and occupational healthfyysinen kuntoPhysical functionBiomarker (medicine)Smoking statusepidemiologyFemaleHEALTHBirth cohortmedicine.medical_specialtyBIOMARKERSfyysinen toimintakyky03 medical and health sciencesphysical functionHumansFRAILTYAgedbusiness.industryMORTALITYDISABILITYagingbiomarkersTelomere HomeostasisTelomere030104 developmental biologyikääntyminenPhysical performancetelomeeritbusinessOlder peopleBody mass index030217 neurology & neurosurgeryDevelopmental BiologyDemographyFollow-Up StudiesMechanisms of ageing and development
researchProduct

Telomere Length and Frailty: The Helsinki Birth Cohort Study

2018

Objectives: Telomere length is associated with aging-related pathologies. Although the association between telomere length and frailty has been studied previously, only a few studies assessing longitudinal changes in telomere length and frailty exist. Design: Longitudinal cohort study. Setting and participants: A subpopulation of the Helsinki Birth Cohort Study consisting of 1078 older adults aged 67 to 79 years born in Helsinki, Finland, between 1934 and 1944. Measures: Relative leukocyte telomere length (LTL) was measured using quantitative real-time polymerase chain reaction at the average ages of 61 and 71 years, and at the latter the participants were assessed for frailty according to …

0301 basic medicineMaleAgingBODY-WATERbiomarkkeritvanheneminenPHENOTYPECohort StudiesRisk FactorsElectric ImpedanceMedicineLongitudinal StudiesLongitudinal cohortOXIDATIVE STRESSGeneral NursingFinlandTelomere ShorteningtelomeregerasteniaFrailtyHealth PolicyConfoundingAge FactorsRISK FACTORta3142General MedicineASSOCIATIONMiddle Aged3. Good healthCohortBody CompositionbiomarkerFemaleBirth cohortLongevityfrailtyta311103 medical and health sciencesSex FactorsINFLAMMATIONHumansELDERLY CHINESERisk factorOLDER-ADULTSAgedbusiness.industryMORTALITYBiomarkerConfidence intervalTelomere030104 developmental biologyPHYSICAL-ACTIVITYCross-Sectional StudiesSocioeconomic FactorsmarkkeritRelative risk3121 General medicine internal medicine and other clinical medicinetelomeeritGeriatrics and Gerontologybusinesshauraus-raihnausoireyhtymäDemographyJournal of the American Medical Directors Association
researchProduct

The Older Finnish Twin Cohort : 45 Years of Follow-up

2019

AbstractThe older Finnish Twin Cohort (FTC) was established in 1974. The baseline survey was in 1975, with two follow-up health surveys in 1981 and 1990. The fourth wave of assessments was done in three parts, with a questionnaire study of twins born during 1945–1957 in 2011–2012, while older twins were interviewed and screened for dementia in two time periods, between 1999 and 2007 for twins born before 1938 and between 2013 and 2017 for twins born in 1938–1944. The content of these wave 4 assessments is described and some initial results are described. In addition, we have invited twin-pairs, based on response to the cohortwide surveys, to participate in detailed in-person studies; these …

0301 basic medicineMaleAgingHORMONE-REPLACEMENT THERAPYphysical activityBLOOD-PRESSURECohort Studies0302 clinical medicineSurveys and QuestionnairesTwins Dizygotickohonnut verenpaineMedicinekohorttitutkimusGenetics (clinical)FinlandBiological Specimen BanksAged 80 and overalcohol1184 Genetics developmental biology physiologyObstetrics and GynecologytwinsMiddle AgedBiobankPOPULATION-BASED TWINepigenetiikkaDEPRESSIVE SYMPTOMSCohortSKELETAL-MUSCLEFemalefyysinen aktiivisuusCohort studyAdulthypertensionAlcohol DrinkinglongitudinalPhysical activityreviewPAIRS DISCORDANTpitkittäistutkimussmokingENVIRONMENTAL-INFLUENCES03 medical and health sciencesTIME PHYSICAL-ACTIVITYtupakointiDiseases in Twinscohort studyDementiaHumansGENOME-WIDE ASSOCIATIONalkoholi (päihteet)Depressive symptomsQuestionnaire studyAgedkaksostutkimusepigeneticsbusiness.industryagingBaseline surveyTwins Monozygoticmedicine.diseasekaksoset030104 developmental biologyikääntyminenPediatrics Perinatology and Child HealthTELOMERE LENGTHbusiness030217 neurology & neurosurgeryDemographyFollow-Up Studiesdementia
researchProduct

Phenotypic spectrum and extent of DNA methylation defects associated with multilocus imprinting disturbances.

2016

Aim: To characterize the genotypic and phenotypic extent of multilocus imprinting disturbances (MLID). Materials &amp; methods: We analyzed 37 patients with imprinting disorders (explorative cohort) for DNA methylation changes using the Infinium HumanMethylation450 BeadChip. For validation, three independent cohorts with imprinting disorders or cardinal features thereof were analyzed (84 patients with imprinting disorders, 52 with growth disorder, 81 with developmental delay). Results: In the explorative cohort 21 individuals showed array-based MLID with each one displaying an Angelman or Temple syndrome phenotype, respectively. Epimutations in ZDBF2 and FAM50B were associated with severe …

0301 basic medicineMaleCancer ResearchDevelopmental DisabilitiesMedizinBiology03 medical and health sciencesGenomic ImprintingGenotypeGeneticsHumansImprinting (psychology)Genetic Association StudiesGeneticsProteinsMethylationSequence Analysis DNATemple SyndromeDNA MethylationPhenotypeDNA-Binding Proteins030104 developmental biologyPhenotypeCase-Control StudiesCohortDNA methylationFemaleEpigenomics
researchProduct

The population genomics of archaeological transition in west Iberia: Investigation of ancient substructure using imputation and haplotype-based metho…

2017

We analyse new genomic data (0.05–2.95x) from 14 ancient individuals from Portugal distributed from the Middle Neolithic (4200–3500 BC) to the Middle Bronze Age (1740–1430 BC) and impute genomewide diploid genotypes in these together with published ancient Eurasians. While discontinuity is evident in the transition to agriculture across the region, sensitive haplotype-based analyses suggest a significant degree of local hunter-gatherer contribution to later Iberian Neolithic populations. A more subtle genetic influx is also apparent in the Bronze Age, detectable from analyses including haplotype sharing with both ancient and modern genomes, D-statistics and Y-chromosome lineages. However, t…

0301 basic medicineMaleCancer ResearchHistoryHereditySteppePopulation geneticsGenetic LinkagePopulation geneticsStone AgeSocial SciencesQH426-470Population genomics0302 clinical medicineddc:590Databases GeneticGenetics(clinical)Sequencing dataGenetics (clinical)MigrationGenetics0303 health sciencesgeography.geographical_feature_categoryGenomeAncient DNAGeographyPaleogeneticsGeologyGenomicsCChumanitiesPositive selectionEuropeGenetic MappingPhylogeographyGeographyBiogeographyArchaeologyNeolithic PeriodlanguageFemaleResearch Articlelcsh:QH426-470GenotypeIntrogressionVariant GenotypesAdmixtureBiologyInsightsAssociation03 medical and health sciencesAgeBronze AgeGeneticsHumansGenetic variationQH426Molecular BiologyEcology Evolution Behavior and Systematics030304 developmental biologyEvolutionary BiologyChromosomes Human YHuman genomePopulation BiologyPortugalGenome HumanHaplotypeEcology and Environmental SciencesBiology and Life SciencesPaleontologyGenetic VariationGeologic TimeDnaSequence Analysis DNAArchaeologylanguage.human_languagePhylogeographylcsh:Genetics030104 developmental biologyAncient DNAGenetics PopulationHaplotypesEvolutionary biologyEarth SciencesIberiaPortuguesePaleogenetics030217 neurology & neurosurgeryImputation (genetics)Population GeneticsPLoS Genetics
researchProduct

Identification of a new locus and validation of previously reported loci showing differential methylation associated with smoking. The REGICOR study.

2015

Smoking increases the risk of many diseases and could act through changes in DNA methylation patterns. The aims of this study were to determine the association between smoking and DNA methylation throughout the genome at cytosine-phosphate-guanine (CpG) site level and genomic regions. A discovery cross-sectional epigenome-wide association study nested in the follow-up of the REGICOR cohort was designed and included 645 individuals. Blood DNA methylation was assessed using the Illumina HumanMethylation450 BeadChip. Smoking status was self-reported using a standardized questionnaire. We identified 66 differentially methylated CpG sites associated with smoking, located in 38 genes. In most of …

0301 basic medicineMaleCancer ResearchLocus (genetics)Genome-wide association study030105 genetics & heredityBiologyBioinformaticsEpigenesis GeneticEpigènesiCohort StudiesThrombospondin 103 medical and health sciencesTabaquismeHumansEpigeneticsMolecular BiologyAgedGeneticsRegulation of gene expressionGene Expression ProfilingSmokingMethylationDNA MethylationMiddle AgedGene expression profiling030104 developmental biologyCross-Sectional StudiesCpG siteGene Expression RegulationDNA methylationCpG IslandsFemaleCarrier ProteinsCorrigendumResearch PaperGenome-Wide Association StudyEpigenetics
researchProduct